The Readout Loud STAT
-
- Business
-
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
-
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation. We also discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.
-
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.
Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc. -
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a surprise announcement. -
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.
Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc. -
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and how we managed to make 300 episodes of this podcast.
Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc. -
299: Live! From the STAT Breakthrough Summit East
Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of course, pie.
Customer Reviews
Great Podcast
Amazing content — the podcast hosts really understand the biopharma field (both the science and history) and their jokes are also quite funny.
Good but could be better
This podcast does a good job of tackling developments in Biotech and boiling down complex subjects into cliff notes versions for listeners who want to get a quick overview of what is happening in the industry. The hosts are smart and entertaining but can be overly judgmental and “know-it-alls” in their commentary. After all, they are reporting on brilliant innovation and amazing science, not actually creating brilliant innovation and amazing science.
Hosts have technical knowledge but could benefit from journalism or communications courses
I want to dive deeper into the pharma market, and this podcast helps get there maybe 65% of the way.
My issue is that some (not all) of the hosts can be very inarticulate. Sometimes there’s a lot of stuttering or awkward pauses as they communicate their thoughts. It can come across as them being unprepared — which maybe is the format?